Potent/NN
and/CC
stable/JJ
attenuation/NN
of/IN
live-HIV-1/NN
by/IN
gain/NN
of/IN
a/DT
proteolysis-resistant/JJ
inhibitor/NN
of/IN
NF-kappaB/NN
(/(
IkappaB-alphaS32/36A/NN
)/)
and/CC
the/DT
implications/NNS
for/IN
vaccine/NN
development/NN
./.

Live-attenuated/JJ
human/JJ
immunodeficiency/NN
viruses/NNS
(/(
HIVs/NNS
)/)
are/VBP
candidates/NNS
for/IN
Acquired/VBN
Immunodeficiency/NN
Syndrome/NN
(/(
AIDS/NN
)/)
vaccine/NN
./.
=====
Based/VBN
on/IN
the/DT
simian/JJ
immunodeficiency/NN
virus/NN
(/(
SIV/NN
)/)
model/NN
for/IN
AIDS/NN
,/,
loss-of-function/NN
(/(
e.g./FW
deletion/NN
of/IN
accessory/NN
genes/NNS
such/JJ
as/IN
nef/NN
)/)
has/VBZ
been/VBN
forwarded/VBN
as/IN
a/DT
primary/JJ
approach/NN
for/IN
creating/VBG
enfeebled/JJ
,/,
but/CC
replication-competent/JJ
,/,
HIV-1/SIV/NN
./.
=====
Regrettably/RB
,/,
recent/JJ
evidence/NN
suggests/VBZ
that/IN
loss-of-function/NN
alone/RB
is/VBZ
not/RB
always/RB
sufficient/JJ
to/TO
prevent/VB
the/DT
emergence/NN
of/IN
virulent/JJ
mutants/NNS
./.
=====
New/NN
strategies/NNS
that/WDT
attenuate/VBP
via/IN
mechanisms/NNS
distinct/JJ
from/IN
loss-of-function/NN
are/VBP
needed/VBN
for/IN
enhancing/VBG
the/DT
safety/NN
phenotype/NN
of/IN
viral/JJ
genome/NN
./.
=====
Here/RB
,/,
we/PRP
propose/VBP
gain-of-function/NN
to/TO
be/VB
used/VBN
simultaneously/RB
with/IN
loss-of-function/NN
as/IN
a/DT
novel/JJ
approach/NN
for/IN
attenuating/VBG
HIV-1/NN
./.
=====
We/PRP
have/VBP
constructed/VBN
an/DT
HIV-1/NN
genome/NN
carrying/VBG
the/DT
cDNA/NN
of/IN
a/DT
proteolysis-resistant/JJ
nuclear/JJ
factor-kappaB/NN
inhibitor/NN
(/(
IkappaB-alphaS32/36A/NN
)/)
in/IN
the/DT
nef/NN
region/NN
./.
=====
HIV-1/NN
expressing/VBG
IkappaB-alphaS32/36A/NN
down-regulates/VBZ
viral/JJ
expression/NN
and/CC
is/VBZ
highly/RB
attenuated/VBN
in/IN
both/CC
Jurkat/NN
and/CC
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
./.
=====
We/PRP
provide/VBP
formal/JJ
proof/NN
that/IN
the/DT
phenotypic/JJ
and/CC
attenuating/NN
characteristics/NNS
of/IN
IkappaB-alphaS32/36A/NN
permit/VBP
its/PRP$
stable/JJ
maintenance/NN
in/IN
a/DT
live/JJ
,/,
replicating/VBG
HIV-1/NN
despite/IN
180/CD
days/NNS
of/IN
forced/JJ
ex/FW
vivo/FW
passaging/NN
in/IN
tissue/NN
culture/NN
./.
=====
As/IN
compared/VBN
with/IN
other/JJ
open-reading/JJ
frames/NNS
embedded/JJ
into/IN
HIV/SIV/NN
genome/NN
,/,
this/DT
degree/NN
of/IN
stability/NN
is/VBZ
unprecedented/JJ
./.
=====
Thus/RB
,/,
IkappaB-alphaS32/36A/NN
offers/VBZ
proof-of-principle/NN
that/IN
artifactually/RB
gained/VBN
functions/NNS
,/,
when/WRB
used/VBN
to/TO
attenuate/VB
the/DT
replication/NN
of/IN
live/JJ
HIV-1/NN
,/,
can/MD
be/VB
stable/JJ
./.
=====
These/DT
findings/NNS
illustrate/VBP
gain-of-function/NN
as/IN
a/DT
feasible/JJ
strategy/NN
for/IN
developing/VBG
safer/JJR
live-attenuated/JJ
HIVs/NNS
to/TO
be/VB
tested/VBN
as/IN
candidates/NNS
for/IN
AIDS/NN
vaccine/NN
./.